These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35142667)

  • 1. Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer's disease.
    Mansour HM; Fawzy HM; El-Khatib AS; Khattab MM
    Neural Regen Res; 2022 Sep; 17(9):1913-1918. PubMed ID: 35142667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Repositioning of Anti-cancer EGFR Inhibitors in Alzheimer's Disease: Current Perspectives and Challenging Prospects.
    Mansour HM; Fawzy HM; El-Khatib AS; Khattab MM
    Neuroscience; 2021 Aug; 469():191-196. PubMed ID: 34139302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries.
    Tavassoly O; Sato T; Tavassoly I
    Mol Pharmacol; 2020 Jul; 98(1):13-22. PubMed ID: 32350120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer's disease.
    Venigalla M; Gyengesi E; Münch G
    Neural Regen Res; 2015 Aug; 10(8):1181-5. PubMed ID: 26487830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin in Traumatic Brain Injury and Cognition.
    Blum B; Kaushal S; Khan S; Kim JH; Alvarez Villalba CL
    Cureus; 2021 Sep; 13(9):e17776. PubMed ID: 34659987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sesame oil mitigates memory impairment, oxidative stress, and neurodegeneration in a rat model of Alzheimer's disease. A pivotal role of NF-κB/p38MAPK/BDNF/PPAR-γ pathways.
    Mohamed EA; Ahmed HI; Zaky HS; Badr AM
    J Ethnopharmacol; 2021 Mar; 267():113468. PubMed ID: 33049345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential predictors of hippocampal atrophy in Alzheimer's disease.
    Dhikav V; Anand K
    Drugs Aging; 2011 Jan; 28(1):1-11. PubMed ID: 21174483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choroid plexus tumor necrosis factor receptor 1: A new neuroinflammatory piece of the complex Alzheimer's disease puzzle.
    Steeland S; Vandenbroucke RE
    Neural Regen Res; 2019 Jul; 14(7):1144-1147. PubMed ID: 30804238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C
    Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-cholinergic strategies for treating and preventing Alzheimer's disease.
    Doraiswamy PM
    CNS Drugs; 2002; 16(12):811-24. PubMed ID: 12421115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacology of Alzheimer's disease: where do we go from here?].
    Sellal F; Nieoullon A; Michel G; Michel BF; Lacomblez L; Geerts H; Delini-Stula A; Bentué-Ferrer D; Bordet R; Allain H
    Therapie; 2005; 60(2):89-107. PubMed ID: 15969312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mitochondrial pyruvate carrier 1 by lapatinib ditosylate mitigates Alzheimer's-like disease in D-galactose/ovariectomized rats.
    Mansour HM; Fawzy HM; El-Khatib AS; Khattab MM
    Neurochem Int; 2021 Nov; 150():105178. PubMed ID: 34481907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease; taking the edge off with cannabinoids?
    Campbell VA; Gowran A
    Br J Pharmacol; 2007 Nov; 152(5):655-62. PubMed ID: 17828287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological basis of drug therapy of Alzheimer's disease.
    Sharma A; Parikh V; Singh M
    Indian J Exp Biol; 1997 Nov; 35(11):1146-55. PubMed ID: 9567741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic stress as a risk factor for Alzheimer's disease: Roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress.
    Bisht K; Sharma K; Tremblay MÈ
    Neurobiol Stress; 2018 Nov; 9():9-21. PubMed ID: 29992181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.